Through the multiyear partnership, Moderna will use Caris’ library of deidentified data to advance the company’s oncology pipeline. Additionally, the partnership will focus on facilitating clinical trial design, discovering new biomarkers and characterizing resistance mechanisms, according to an Oct. 24 Caris news release.
Financial terms of the partnership were not disclosed.
“We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives,” David Spetzler, PhD, president of Caris Life Sciences, said in the news release. “The aggregate strength of our combined molecular, data science and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna’s innovative medicines.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
